From: Predictors for an unsuccessful INtubation-SURfactant-Extubation procedure: a cohort study
Post-surfactant characteristics | Treatment group | |||
---|---|---|---|---|
INSURE success (n = 100) | INSURE failure (n = 33) | Short MV (n = 31) | Long MV (n = 158) | |
CRIB-score, median (IQR)3 | 2 (1–2) | 2 (2–6)* | 2 (2–5)* | 6 (2–8)* |
CRIB-score > 4, n (%)3 | 6 (8) | 9 (32)* | 9 (36)* | 79 (66)* |
Given < 6 hours after surfactant: | ||||
Inotropes, n (%)2 | 2 (2) | 5 (15)* | 1 (3) | 56 (35)* |
Packed red blood cells, n (%)2 | 6 (6) | 3 (9) | 1 (3) | 18 (11) |
Volume expansion, n (%)2 | 10 (10) | 5 (15) | 5 (16) | 72 (46)* |
Antibiotics ≥ 7 days, n (%)2 | 17 (17) | 6 (18) | 12 (39)* | 61 (39)* |
Pneumothorax2 | 2 (2) | 8 (25)* | 1 (3) | 35 (23)* |
Necrotizing enterocolitis, n (%)2 | 10 (10) | 8 (24)* | 4 (13) | 56 (36)* |
Clinical suspicion or x-ray changes | 9 | 5 | 4 | 50 |
Surgery | 1 | 3 | 0 | 6 |
Patent ductus arteriosus on first echocardiography, n (%)2 | 33 (33) | 16 (48) | 13 (42) | 71 (45) |
No treatment | 19 | 11 | 11 | 49 |
NSAID/surgery | 14 | 5 | 2 | 22 |
Intraventricular hemorrhage, n (%)2 | 38 (38) | 12 (36) | 7 (23) | 73 (46) |
Grades I–II | 34 | 7 | 3 | 32 |
Grades III–IV | 4 | 5 | 4 | 41 |
Periventricular leukomalasia, n (%)2 | 4 (4) | 1 (3) | 2 (6) | 15 (9) |
BPD, n (%)1,4 | 12 (18) | 5 (26) | 4 (24) | 27 (46)* |
Retinopathy of prematurity grade III, n (%)2 | 3 (3) | 1 (3) | 0 (0) | 12 (8) |
MV days, median (IQR)2 | 0.01 (0.00–0.03) | 3.26 (1.59–4.45)* | 0.70 (0.33–0.92)* | 3.26 (1.77–6.98)* |
CPAP days, median (IQR)2 | 17.5 (9.3–31.5) | 21.5 (10.3–33.1) | 19.0 (6.7–34.1) | 22.4 (1.2–36.2) |
Oxygen days, median (IQR)2 | 6 (2–20) | 10 (4–29) | 5 (0–21) | 15 (3–40)* |
Neonatal death < 28 days, n (%)2 | 1 (1) | 4 (12)* | 2 (6) | 41 (26)* |